Daesung Microbiological Labs. Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 14, 2021 at 09:03 pm EST
Share
Daesung Microbiological Labs. Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 5,438.62 million compared to KRW 5,634.19 million a year ago. Net loss was KRW 335 million compared to net income of KRW 265.46 million a year ago. Basic loss per share from continuing operations was KRW 88 compared to basic earnings per share from continuing operations of KRW 69 a year ago. Basic loss per share was KRW 88 compared to basic earnings per share of KRW 69 a year ago.
For the nine months, sales was KRW 0.00021 million compared to KRW 0.00015 million a year ago. Net income was KRW 112.63 million compared to KRW 1,896.44 million a year ago. Basic earnings per share from continuing operations was KRW 29 compared to KRW 499 a year ago. Basic earnings per share was KRW 29 compared to KRW 499 a year ago.
DAESUNG MICROBIOLOGICAL LABS. CO., LTD. is a Korea-based company mainly engaged in the manufacture of animal pharmaceuticals. The Companyâs products consist of vaccines, antibiotics, antibacterials, anthelminthics, mastitis ointments, disinfectants, probiotics and enzyme products, teat dipping disinfectants, metabolites, nutrients, and biologicals used for prevention and treatment of diseases for cattle, swine, poultries and canines. The Company distributes its products within domestic market and to overseas markets, including Southeast Asia, Middle East and Africa.